BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23916459)

  • 1. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.
    Neto MG; Zwirtes R; Brites C
    Braz J Infect Dis; 2013; 17(6):691-700. PubMed ID: 23916459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies.
    Bozkurt B
    Cardiovasc Toxicol; 2004; 4(3):243-60. PubMed ID: 15470272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.
    Rhew DC; Bernal M; Aguilar D; Iloeje U; Goetz MB
    Clin Infect Dis; 2003 Oct; 37(7):959-72. PubMed ID: 13130409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
    Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia related to antiretroviral therapy.
    Estrada V; Portilla J
    AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
    Kotler DP
    J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
    Barbaro G; Barbarini G
    Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
    Haser GC; Sumpio B
    J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
    Barbaro G
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A decade of antiretroviral therapy: a profile of patients with 10 years of highly effective triple therapy].
    Wilson G; Wolff M
    Rev Chilena Infectol; 2012 Jun; 29(3):337-43. PubMed ID: 23096476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.